The “anticommons” problem for FDCs is one of ACCESS and this implicates other factors such as R&D funding mechanisms and global IP rules. Multidisciplinary approaches to the problem are required. The perceptions of the different IPR stakeholders have lead to the evolution of different kinds of transactions. For developing countries, IP-resource poor inventors, NGOs, and patients, creative ways are needed to reduce IPR transaction costs with regard to fixed-dose combination drugs.